硫酸吗啡控释片治疗晚期癌症疼痛的临床疗效分析

【目的】观察硫酸吗啡控释片对晚期癌症患者中度疼痛的临床疗效及其安全性研究。【方法】选取64例男性中度癌痛患者，口服美施康定片（每片含盐酸硫酸吗啡15mg）止疼治疗，初始剂量每12h为15mg，根据患者的疼痛情况调整用药剂量，直至患者无痛或基本无痛，连续治疗14d，治疗期间进行疼痛强度、生活质量的评分及不良反应的观察并记录结果。【结果】口服美施康定片（以每片含15mg硫酸吗啡计算）的最终滴定剂量为：≤30mg／d的30例（46．87％），31—45mg／d的22例（34．38％），46～60mg／cl的8例（12．50％），61～75mg／d的2例（3．13％），≥75mg／d的2例（3．13％），总疼痛有效率96．87％。有轻度头痛、头晕、嗜睡、恶心、呕吐、便秘及皮肤瘙痒等不良反应，但发生率较低。【结论】硫酸吗啡控释片片控制中度癌性疼痛效果显著，不良反应较轻，能很好的改善患者的生活质量。

Clinical effect of morphine sulfate sustained release tablets in treating of cancer pain

[Objective] To examine the clinical efficacy and adverse side effects of Morphine sulfate sustained release tablets for the treatment of moderate cancer pain. [ Method ] A total of 64 men sufferred cancer with moderate cancer pain were treated with Morphine sulfate Sustained Release tablets（each piece contains 15 mg of morphine sulfate）. The initial dose was 15 mg per 12 h, and adjusted according to the patients＇ desires until the pain completely disappeared or nearly did so The treatment continued for 14 consecutive days. During treatments period,adverse effects, quality of life and scores for the intensity of pain were observed and recorded. [ Results ] The final titrated dossge of Morphine sulfate （in terms of 15 mg per tablet of morphine sulfate） was as follows： 30 cases（46.87%） received a dosage of ≤ 30 mg/d, 22 cases（34.38%） received a dosage of 31 to 45 mg/d, those in 8 cases（12.50%） received a dosage of 46 to 60 mg/d, 2 cases（3.13%） received a dosage of 61 to 75 mg/d and those in 2 cases（3.13%） received a dosage of ≥ 75 mg/d. The overall rate of relief from moderated pain was 96.87%. Only a few patients had adverse reactions, including mild headache, dizziness, lethargy, nausea, vomiting,constipation and pruitus. [Conclusion] Morphine sulfate sustained release tablets has definite efficacy and slight adverse reaction in the treatment of moderate cancer pain and can improve patient＇s quality of life.